Semaglutide has produced weight loss results that were not achievable with previous medications — average losses of 15% or more of body weight in clinical trials. For patients who have spent years fighting their metabolism, the mechanism behind those results matters. This is not a stimulant or a metabolic accelerant. Semaglutide works by restoring and extending a hormonal signal your body already uses to regulate hunger.
Understanding how semaglutide works helps set realistic expectations, explains why physician supervision matters, and clarifies why the medication is so different from anything that came before it. If you are considering starting a medical weight loss program, the science is worth understanding first.
What Is GLP-1 and Why Does It Matter for Weight Loss?
GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally in the small intestine in response to eating. It is part of the body's built-in satiety system — a signal that tells the brain you have eaten enough and that the meal has been registered.
GLP-1 does several things when released:
- Signals fullness to the brain — GLP-1 acts on hypothalamic receptors to reduce appetite and promote the sensation of satiety
- Slows gastric emptying — food moves more slowly from the stomach into the intestines, extending the sense of fullness after meals
- Stabilizes blood glucose — GLP-1 stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon, reducing post-meal blood sugar spikes
- Reduces appetite signaling — at the level of the central nervous system, GLP-1 reduces the drive to eat and diminishes food-seeking behavior
The problem with naturally occurring GLP-1 is that it has a very short half-life — approximately 2 minutes. It is rapidly degraded by the enzyme DPP-4. The satiety signal it creates is brief. For people with impaired appetite regulation, this natural system is not sufficient to overcome chronic overeating or metabolic dysfunction.
How Semaglutide Mimics Your Body's Hunger Hormone
Semaglutide is a GLP-1 receptor agonist — a synthetic molecule engineered to bind to the same receptors as natural GLP-1, but with dramatically extended duration. Where natural GLP-1 has a half-life of 2 minutes, semaglutide has a half-life of approximately 7 days. A single weekly injection sustains continuous GLP-1 receptor activation throughout the week.
This extended action produces a sustained reduction in appetite rather than a brief post-meal signal. Patients often describe this as a reduction in “food noise” — the constant background thoughts about eating, cravings between meals, and preoccupation with food that many people with obesity experience. The food noise quiets.
The clinical results from this mechanism are well-established. In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), participants with obesity or overweight who received once-weekly semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. More than one in three participants lost 20% or more of their body weight. These are clinical trial averages — individual results vary based on diet, activity, adherence, and health history.
Semaglutide's Three Mechanisms of Action
Semaglutide affects weight through three primary mechanisms in physician-supervised medical weight loss:
- Hypothalamic appetite suppression — GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety signaling. Semaglutide activates these receptors continuously, reducing the neurological drive to eat. This is why patients report not feeling hungry at mealtimes and losing interest in snacking — it is a central nervous system effect, not just a stomach effect.
- Delayed gastric emptying and extended satiety — semaglutide slows the rate at which food leaves the stomach, prolonging the sensation of fullness after meals. Eating less becomes easier because the physical signals of fullness last longer.
- Improved insulin sensitivity and blood glucose regulation — semaglutide enhances insulin secretion in response to elevated blood glucose and suppresses glucagon release. This reduces the blood sugar spikes and crashes that drive hunger and cravings, particularly in patients with insulin resistance or prediabetes.
These three mechanisms work together. The combined effect is a significant reduction in caloric intake without the willpower burden that makes diet-only approaches unsustainable for most patients.
How Tirzepatide Differs — Dual GLP-1 + GIP Agonism
Tirzepatide (the active ingredient in Mounjaro and Zepbound) adds a second receptor target: GIP (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone involved in insulin secretion and fat metabolism. By targeting both GLP-1 and GIP receptors simultaneously, tirzepatide produces additive metabolic effects beyond what either receptor alone can achieve.
In the SURMOUNT-5 trial (Aronne et al., New England Journal of Medicine, 2025), a head-to-head comparison of tirzepatide and semaglutide, participants receiving tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% with semaglutide. Both medications produced clinically significant weight loss — tirzepatide demonstrated greater average efficacy in this direct comparison. For a detailed comparison, see our guide to semaglutide vs. tirzepatide.
Physician Supervision and Dosing — Why It Matters
Semaglutide is not prescribed at a fixed dose. Proper use involves a titration schedule — starting at a low dose and increasing gradually over 4–8 weeks to reach the therapeutic range. This approach minimizes gastrointestinal side effects (particularly nausea) while allowing the body to adapt to the medication.
A standard titration schedule begins at 0.25 mg weekly for the first four weeks, progressing upward in increments based on tolerability and response. The therapeutic dose for weight management is typically 2.4 mg weekly (the Wegovy dosing range). Patients prescribed through telehealth apps on preset escalation schedules often experience more side effects because the schedule is not adapted to their individual response.
At Vitality, the titration pace is physician-guided. Dr. Jaqua reviews labs before prescribing — fasting glucose, HbA1c, thyroid function, and kidney and liver function — to confirm candidacy and rule out contraindications. Dose adjustments are made based on patient response at check-ins, not a calendar.
Self-prescribing semaglutide from unverified sources is dangerous for several reasons: no evaluation of contraindications, no dose titration oversight, no monitoring for adverse effects, and no ability to distinguish normal side effects from warning signs that warrant dose reduction or discontinuation.
What Semaglutide Cannot Do Alone
Semaglutide produces its best results as part of a physician-supervised program that includes lifestyle support. The medication changes appetite signaling — it does not change metabolic rate, build muscle, or address hormonal contributors to weight gain (such as low testosterone in men or thyroid dysfunction).
Protein intake and resistance exercise are particularly important during semaglutide treatment. Because the medication reduces overall caloric intake, patients who do not maintain adequate protein and resistance training may lose a higher proportion of lean mass along with fat mass. Vitality's approach addresses this: nutritional guidance is part of the program.
Weight loss plateaus are normal and expected at various points during treatment. A plateau typically indicates that metabolism has adjusted to the lower caloric intake. Options include dose adjustment, dietary modification, or lifestyle changes — all of which are physician-guided decisions.
For more information about starting a physician-supervised program, visit our GLP-1 weight loss program page or book a free consultation to review your labs and candidacy with Dr. Jaqua.
Frequently Asked Questions
Is semaglutide FDA-approved?
Semaglutide is FDA-approved in two formulations: Ozempic (approved for type 2 diabetes management) and Wegovy (approved for chronic weight management in adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition). Compounded semaglutide prescribed through a licensed 503A pharmacy is a distinct formulation and is not FDA-approved. It is prescribed as a patient-specific compounded medication under physician supervision.
How is semaglutide different from diet pills?
Traditional diet pills typically work through stimulant mechanisms — increasing energy expenditure, reducing fat absorption, or suppressing appetite via central nervous system stimulation. Semaglutide works through a fundamentally different pathway: it mimics GLP-1, a naturally occurring gut hormone your body already produces in response to eating. Rather than forcing an abnormal state, semaglutide enhances and extends a normal hormonal response. The result is more durable appetite regulation and metabolic improvements that older diet medications could not achieve.
How quickly does semaglutide start working?
Most patients notice a reduction in appetite and food cravings within the first 1–2 weeks at the starting dose. Measurable weight loss typically begins during weeks 4–8 as the dose increases into the therapeutic range. The full effect of semaglutide on body weight develops over months — not days. In the STEP 1 trial, the most significant weight loss occurred progressively over 68 weeks of treatment.
Can I stop taking semaglutide once I reach my goal weight?
Stopping semaglutide typically results in weight regain over time. The STEP 4 trial demonstrated that patients who discontinued semaglutide after 20 weeks of treatment regained most of their weight within 52 weeks. For many patients, semaglutide functions as a long-term maintenance medication rather than a short course. Dr. Jaqua discusses the maintenance strategy as part of the initial treatment plan — including what lifestyle changes need to be in place to support tapering if that is the goal.
References
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384:989–1002. (STEP 1 trial)
- Aronne LJ, et al. “Tirzepatide vs. Semaglutide Once Weekly in Patients with Obesity.” New England Journal of Medicine. 2025. (SURMOUNT-5 trial)